Efficacy of SNRI Treatment on Prefrontality in Patients With GAD and Other Comorbities

Efficacy of Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) Treatment on Prefrontality in Patients With Generalized Anxiety Disorder (GAD) and Other Comorbidities

This is an open-label flexible-dose pilot study evaluating the efficacy, safety, and tolerability of Pristiq (desvenlafaxine) in outpatient subjects diagnosed with Generalized Anxiety Disorder (GAD) with or without comorbidities that are secondary to the GAD. Primary trial objective is to evaluate the efficacy of Pristiq (desvenlafaxine) SNRI treatment 50 to 100 mg once daily in the treatment of GAD with or without comorbidities. Secondary trial objective is to determine whether or not treatment outcome in GAD is related to changes in cortical prefrontal activity of norepinephrine.

Study Overview

• Status: Completed
• Conditions: Generalized Anxiety Disorder
• Intervention / Treatment: Drug: Desvenlafaxine

• Study Type: Interventional
• Enrollment (Actual): 29
• Phase: Phase 4

Contacts and Locations

Study Locations

• Canada
  • Ontario
    • Toronto, Ontario, Canada, M4W 2N4
      • START Clinic for Mood and Anxiety Disorders

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 63 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• The patient has provided signed informed consent.
• Outpatients aged 18-65 (extremes included).
• Patients with a primary diagnosis of GAD according to DSM IV (300.23) criteria (diagnosis to be made using the Mini International Neuropsychiatric Interview; MINI Version 6.0.0). Patients with co-morbid anxiety disorders will be permitted, as long as GAD is judged to be the primary diagnosis.
• Patients who score a HAM-A of ≥ 20 at both Screening and Baseline, and ≥ 10 on the psychic and somatic anxiety factors.
• On the basis of physical examination, medical history, and basic laboratory screening, patient is, in the investigator's opinion, in a suitable condition.
• Willing and able to attend study appointments in the correct time windows.

Exclusion Criteria:

• Any other axis I diagnosis that was a primary disorder in the previous six months.
• Alcohol or drug abuse as defined in the DSM IV (300.23) within the last six months.
• Mania, hypomania as defined in the DSM IV (300.23).
• Any psychotic disorder.
• Eating disorders as defined in the DSM IV (300.23).
• Any cognitive disorder or dementia within 3 months before the baseline visit.
• Clinical interpretation of apparent suicide risk.
• Continuation or commencement of formal psychotherapy.
• Current use of or commencement of antidepressant and anxiolytic medications.
• Failure on no more than 2 antidepressants (either SSRIs or SNRIs to exclude any treatment resistance.
• Patients, who have been on an antidepressant or other anxiolytic prior to the study, will have discontinued it more than two weeks prior to entry into the study. Those who have been on fluoxetine, will have been off of it for at least 5 weeks.
• Patients who have been on a herbal or alternative treatment judged to be potentially anxiolytic or with psychobiological activity (e.g. St. John's Wort, S-adenosylmethionine), will have terminated usage of the agent more than two weeks prior to entering the study.
• Scores on the Hamilton Depression Rating Scale (HAM-D) > 15, at screening visit 1
• Laboratory values at screening or in medical history that may be considered through clinical interpretation to be significant.
• Diseases that could through clinical interpretation interfere with the assessments of safety, tolerability and efficacy.
• Serious illness: Liver or renal insufficiency, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, infectious, neoplastic or metabolic disturbance.
• If female, the subject is pregnant or lactating or intending to become pregnant before, during or within 30 days after participating in this study; or intending to donate ova during such time period.
• The subject has received electroconvulsive therapy, vagal nerve stimulation, or repetitive transcranial magnetic stimulation within 6 months prior to Screening.
• The patient is, in the opinion of the investigator, unlikely to comply with the clinical trial protocol or is unsuitable for any reason.
• Known allergy or intolerance to desvenlafaxine or its excipients.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Desvenlafaxine; At the screening visit those who are eligible will enter a randomized trial with Pristiq (desvenlafaxine) 50 to 100 mg. The study will begin with a single week of Pristiq (desvenlafaxine) 50mg. Subsequently, tablets will be administered in a flexible dose fashion and patients will be followed up weekly (biweekly after week 8) and at the investigators discretion. After the first week the patients' dosage will be increased up to a maximum of 100 mg daily. This dose will remain fixed after 8 weeks of treatment until week 16.

Drug: Desvenlafaxine; Other Names: Pristiq

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Mean changes in the Hamilton Anxiety Rating Scale from baseline visit to week 16.	16 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
Mean change from baseline to week 16 on the measures of prefrontality including: Frontal System Behavioural Scale and Behaviour Rating Inventory of Executive Function-Adult	16 weeks

Collaborators and Investigators

• Sponsor: START Clinic for Mood and Anxiety Disorders

Study record dates

Study Major Dates

• Study Start: January 1, 2013
• Primary Completion (Actual): April 15, 2020
• Study Completion (Actual): May 1, 2020

Study Registration Dates

• First Submitted: October 23, 2013
• First Submitted That Met QC Criteria: October 28, 2013
• First Posted (Estimate): November 3, 2013

Study Record Updates

• Last Update Posted (Actual): October 23, 2020
• Last Update Submitted That Met QC Criteria: October 21, 2020
• Last Verified: October 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Anxiety Disorders; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Psychotropic Drugs; Neurotransmitter Uptake Inhibitors; Membrane Transport Modulators; Antidepressive Agents; Serotonin and Noradrenaline Reuptake Inhibitors; Desvenlafaxine Succinate
• Other Study ID Numbers: WS2382578

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided